Heron Therapeutics Inc (HRTX)
2.61
+0.06
(+2.35%)
USD |
NASDAQ |
May 03, 16:00
2.605
0.00 (0.00%)
After-Hours: 20:00
Heron Therapeutics Enterprise Value: 485.70M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 03, 2024 | 485.70M |
May 02, 2024 | 476.68M |
May 01, 2024 | 445.11M |
April 30, 2024 | 442.11M |
April 29, 2024 | 469.17M |
April 26, 2024 | 461.65M |
April 25, 2024 | 476.68M |
April 24, 2024 | 491.71M |
April 23, 2024 | 514.26M |
April 22, 2024 | 482.70M |
April 19, 2024 | 490.21M |
April 18, 2024 | 500.73M |
April 17, 2024 | 509.75M |
April 16, 2024 | 533.81M |
April 15, 2024 | 536.81M |
April 12, 2024 | 530.80M |
April 11, 2024 | 535.31M |
April 10, 2024 | 503.74M |
April 09, 2024 | 514.26M |
April 08, 2024 | 506.75M |
April 05, 2024 | 506.75M |
April 04, 2024 | 479.69M |
April 03, 2024 | 479.69M |
April 02, 2024 | 476.68M |
April 01, 2024 | 500.73M |
Date | Value |
---|---|
March 28, 2024 | 509.75M |
March 27, 2024 | 505.24M |
March 26, 2024 | 505.24M |
March 25, 2024 | 536.81M |
March 22, 2024 | 539.82M |
March 21, 2024 | 551.85M |
March 20, 2024 | 551.85M |
March 19, 2024 | 536.81M |
March 18, 2024 | 538.32M |
March 15, 2024 | 553.35M |
March 14, 2024 | 551.85M |
March 13, 2024 | 545.83M |
March 12, 2024 | 448.12M |
March 11, 2024 | 455.64M |
March 08, 2024 | 484.20M |
March 07, 2024 | 482.70M |
March 06, 2024 | 466.16M |
March 05, 2024 | 478.19M |
March 04, 2024 | 477.43M |
March 01, 2024 | 485.70M |
February 29, 2024 | 493.22M |
February 28, 2024 | 499.23M |
February 27, 2024 | 505.12M |
February 26, 2024 | 484.08M |
February 23, 2024 | 484.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
177.09M
Minimum
Nov 14 2023
2.145B
Maximum
Dec 03 2019
874.18M
Average
936.00M
Median
Nov 22 2021
Enterprise Value Benchmarks
United Therapeutics Corp | 9.534B |
Esperion Therapeutics Inc | 564.26M |
Aldeyra Therapeutics Inc | 117.33M |
Ocular Therapeutix Inc | 796.15M |
Alpine Immune Sciences Inc | 3.908B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -10.72M |
Revenue (Quarterly) | 34.23M |
Total Expenses (Quarterly) | 44.45M |
EPS Diluted (Quarterly) | -0.05 |
Gross Profit Margin (Quarterly) | 71.12% |
Profit Margin (Quarterly) | -31.33% |
Earnings Yield | -32.18% |
Normalized Earnings Yield | -32.18 |